GGPS1

GGPS1 encodes geranylgeranyl diphosphate (GGPP) synthase, which catalyzes the synthesis of GGPP from farnesyl diphosphate and isopentenyl diphosphate, an activity established by in vitro enzymatic reconstitution and functional complementation (PMID:10101267). GGPP is the obligate lipid donor for geranylgeranylation of small GTPases, and loss of GGPS1 impairs this prenylation across multiple tissues: in myometrial smooth muscle, GGPP is required for RhoA geranylgeranylation that drives the RhoA/Rock2/p-MLC contractile pathway, with exogenous GGPP or farnesyl pyrophosphate rescuing the contraction defect (PMID:33340314). GGPS1-derived GGPP also controls the membrane localization and function of Rab GTPases—supporting Rab10/TLR4 membrane positioning and NLRP3 inflammasome activation (PMID:30652497) and restraining Rab37-mediated autophagy in lung injury (PMID:35334098)—and in chondrocytes it normally suppresses BMP2/Smad/Runx2 osteogenic signaling (PMID:28357594). Biallelic pathogenic GGPS1 variants impair small-GTPase geranylgeranylation and delay myogenic membrane repair, causing a human syndrome with muscular dystrophy, while a Y259C knock-in is prenatally lethal in mice, establishing the enzyme as essential for muscle membrane healing and viability (PMID:32403198).

1. 1999 High

   Established the core biochemical identity of GGPS1 by showing its product catalyzes GGPP formation from defined isoprenoid substrates, defining the enzyme that supplies the geranylgeranyl lipid donor.

   Evidence Recombinant expression in E. coli with in vitro enzymatic assay and carotenoid-synthesis functional complementation

   PMID:10101267

   Open questions at the time

   • Does not address tissue-specific roles or downstream prenylation targets
   • No structural basis for substrate specificity established
2. 2017 Medium

   Showed that GGPS1-derived GGPP acts as a brake on osteogenic differentiation, linking the enzyme to BMP2/Smad/Runx2 signaling in chondrocytes.

   Evidence Tamoxifen-inducible Col2-CreERT2 chondrocyte-specific Ggps1 knockout in a fracture-healing model with pathway analysis

   PMID:28357594

   Open questions at the time

   • The specific prenylated GTPase mediating BMP2 suppression is not identified
   • Single-lab finding without rescue by GGPP supplementation
3. 2019 Medium

   Connected GGPP supply to innate immune signaling by showing GGPS1 loss mislocalizes Rab10 and TLR4 and dampens NLRP3 inflammasome activation.

   Evidence Lung-specific GGPPS1 knockout mice in an LPS acute lung injury model with membrane-localization immunofluorescence and pathway readouts

   PMID:30652497

   Open questions at the time

   • Direct geranylgeranylation of Rab10 not biochemically demonstrated here
   • Single-lab study
4. 2020 High

   Established human disease relevance and physiological essentiality by linking biallelic GGPS1 variants to impaired small-GTPase geranylgeranylation, defective muscle membrane repair, and embryonic lethality.

   Evidence Whole exome sequencing across 6 families, laser membrane-injury assay in patient myogenic cells, and Y259C knock-in mouse

   PMID:32403198

   Open questions at the time

   • The specific GTPase whose under-prenylation causes membrane-repair failure is not pinpointed
   • Mechanism linking enzyme loss to hearing and ovarian phenotypes not resolved
5. 2021 High

   Provided direct mechanistic proof that GGPP enables RhoA geranylgeranylation to drive smooth muscle contraction, with rescue establishing causality.

   Evidence Myometrial-specific Ggps1 knockout with RhoA prenylation/localization assays and GGPP/FPP supplementation rescue

   PMID:33340314

   Open questions at the time

   • Whether the same RhoA axis operates in non-uterine smooth muscle not tested
   • Does not address other GGPP-dependent GTPases in the same tissue
6. 2021 Low

   Proposed upstream transcriptional/post-transcriptional control of GGPS1 via a miR-182 axis exploitable pharmacologically.

   Evidence In vivo LPS-ALI mouse model with CMAP drug identification and miR-182/GGPPS1 pathway analysis

   PMID:34845949

   Open questions at the time

   • Direct miR-182 binding to GGPS1 mRNA not validated
   • Single study, single lab
7. 2022 Medium

   Positioned GGPS1 upstream of Rab37-dependent autophagy, showing its loss restrains autophagic signaling during ventilator-induced lung injury.

   Evidence Lung-specific GGPPS1 knockout with TEM autophagosome quantification and Rab37 overexpression rescue

   PMID:35334098

   Open questions at the time

   • Whether GGPS1 controls Rab37 via prenylation or expression is not disentangled
   • Single-lab finding
8. 2026 Medium

   Linked a regulatory GGPS1 promoter variant to reduced enzyme expression and a renal phenotype, extending functional consequences of GGPS1 dosage.

   Evidence Promoter activity (luciferase) assay, IHC/Western in patient tissue, and regression analysis in 77 patients

   PMID:41800173

   Open questions at the time

   • Causal mechanism connecting reduced GGPP to cyst enlargement not defined
   • Correlative clinical association, modest cohort

• It remains unresolved how a single biochemical activity—GGPP synthesis—produces tissue-restricted phenotypes through distinct downstream GTPases, and which specific prenylation targets mediate the human disease manifestations.
• No unified accounting of which GTPase under-prenylation drives muscle, hearing, and ovarian phenotypes
• No structural model of substrate handling
• No direct biochemical prenylation assay for each implicated GTPase in disease tissue